Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
FatCamera/E+ via Getty Images
The fool doth think he is wise, but the wise man knows himself to be a fool. ― William Shakespeare
Today, we revisit a midcap biopharma name for the first time since we did an in-depth piece on it late in 2019. The company…
